#Taipei #USA #Multiple System Atrophy #YA-101 #Dasher Neuroscience

Dasher Neuroscience Advances with YA-101 Clinical Trials

Dasher Neuroscience Holdings Inc. has made significant strides in the development of its lead AI-driven therapeutic candidate, YA-101, targeting the rare and rapidly progressive condition known as Multiple System Atrophy (MSA). The company recently announced the successful completion of patient recruitment for its global, multicentric Phase 2 clinical trial, an important milestone that paves the way for further advancements towards clinical commercialization.

The Phase 2 trial is set against the backdrop of a critical medical need. MSA is characterized by neurodegeneration and rapidly leads to severe disabilities, with most patients facing a life expectancy of only six to ten years post-diagnosis. Current treatment options focus solely on symptomatic relief, underscoring the urgent demand for innovative therapies that modify disease progression.

Encouraging Progress and Collaborative Efforts

Dasher Neuroscience's CEO, Dr. Jane Tseng, expressed her optimism regarding the trial, stating, _"Completing patient recruitment for this Phase 2 global study is a major leap forward for our lead candidate, YA-101. This study aims to provide crucial data on the safety and clinical efficacy of the drug, laying a solid foundation for potential licensing discussions with global partners as we strive to bring this groundbreaking therapy to patients in need of hope."

The recruitment efforts have successfully enrolled 90 participants across clinical sites in the United States, Japan, and Taiwan. Patients in the trial are aged 30 and older and have been diagnosed with MSA based on Movement Disorder Society (MDS) criteria, which include both parkinsonian and cerebellar subtypes.

Trial Design and Outcome Measures

The Phase 2 clinical trial is meticulously designed as a double-blind, placebo-controlled, dose-escalation study. It aims to evaluate several key factors, such as safety, tolerability, pharmacokinetics, and clinical efficacy of YA-101 in the target demographic.

The primary endpoint of the study focuses on the incidence and severity of adverse events, while secondary measures will provide insights into behavior modifications through pharmacokinetic parameters and clinical effectiveness assessed via the Unified MSA Rating Scale and the 10-Meter Walk Test.

Regulatory Designations

YA-101 has received the Fast Track designation from the U.S. Food and Drug Administration (FDA) as well as orphan drug status from regulatory agencies in the United States, Japan, and the European Union. These designations highlight the drug's potential to meet an unmet medical need and expedite its development and review process.

The Urgency of Treatment for MSA

Multiple System Atrophy, a rare neurodegenerative disorder, has an estimated global prevalence of around five cases per 100,000 individuals, translating to an alarming number of affected patients. In the United States alone, between 15,000 and 50,000 people are living with this condition; the numbers rise significantly within European countries, Japan, and Taiwan.

After gaining regulatory approval, YA-101 aims to address the formidable gap in treatment options available for MSA, ultimately providing new avenues of hope and therapeutic intervention for those afflicted with this life-altering condition.

About Dasher Neuroscience Holdings Inc.

Dasher Neuroscience is publicly traded on the Emerging Stock Market of Taiwan under the ticker TPEx 7829. As an AI-focused biopharmaceutical company, it is dedicated to leveraging innovative technology to expedite the development of central nervous system therapies. YA-101 is just one of several candidates in their pipeline, with additional projects targeting Parkinson's disease, Alzheimer's, and schizophrenia.

The company’s commitment towards solving unmet medical needs continues to drive its mission, ensuring that safe and effective therapeutic options are available for those in desperate need. For further information, you can visit Dasher Neuroscience's official website at dasherneuroscience.com.